<SEC-DOCUMENT>0001062993-17-002196.txt : 20170504
<SEC-HEADER>0001062993-17-002196.hdr.sgml : 20170504
<ACCEPTANCE-DATETIME>20170504131824
ACCESSION NUMBER:		0001062993-17-002196
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170502
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170504
DATE AS OF CHANGE:		20170504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17813099

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>May 2,
2017 </U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></U><BR></B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
    <TD align=center width="33%"><B><U>20-2000871 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
    <TD align=center width="50%"><U><B>V1X 3M4</B></U><B> </B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424 </U></B></P>
<P align=center><B><U>N/A </U><BR></B>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) <BR>[&nbsp;&nbsp; ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp; ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) <BR>[&nbsp;&nbsp; ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 7.01 </B></TD>
    <TD align=left width="90%"><B>Regulation FD Disclosure
</B></TD></TR></TABLE>
<P align=justify>A copy of the news release announcing that Lexaria will
implement a $1 million combined research and development (&#147;R&amp;D&#148;) and
intellectual property (&#147;IP&#148;) budget. is filed as exhibit 99.1 to this current
report and is hereby incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 9.01 </B></TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits
  </B></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee ><A
      href="exhibit99-1.htm">99.1 </A></TD>
    <TD bgColor=#eeeeee><A href="exhibit99-1.htm">
      <P align=justify>Press Release dated May 2,
2017</P></A></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left><B>LEXARIA BIOSCIENCE CORP.</B> </TD></TR>
  <TR>
    <TD>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer
</TD></TR></TABLE></DIV><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=top>
    <TD align=left >Date: </TD>
    <TD align=left width="90%">May 3, 2017 </TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1</B></P>
<P align=center><B>Lexaria Announces Million Dollar Research and Development
Program </B></P>
<P align=justify>Kelowna, BC / May 2, 2017 / Lexaria Bioscience Corp
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148;, &#147;Lexaria&#148;) announces a $1 million
combined research and development (&#147;R&amp;D&#148;) and intellectual property (&#147;IP&#148;)
budget.</P>
<P align=justify>Lexaria&#146;s R&amp;D program is expected to begin in June 2017 and
be comprised of studies both inclusive of and also complementary to its
collaborative R&amp;D with Canada&#146;s National Research Council (&#147;NRC&#148;). Lexaria&#146;s
R&amp;D budget is fully funded from existing capital, applying existing funds.
</P>
<P align=justify>The Lexaria R&amp;D will include many studies; and their
objectives, design, and results will be reported as available. Lexaria&#146;s patent
applications name several groups of molecules, all of which will be studied
within this budget: </P>
<P align=justify>Cannabinoids; <BR>Vitamins; <BR>NSAIDs; and, <BR>Nicotine.</P>
<P align=justify>The R&amp;D will include <I>in vitro</I> absorption studies
utilizing Lexaria&#146;s technology to examine improvements in absorption across
human intestinal tissue. For the first time ever Lexaria will also conduct <I>in
vivo</I> (animal) studies, designed to provide more detailed information on
whole-body reactions to efficient and rapid delivery of these various payload
molecules. The <I>in vivo</I> studies are expected to significantly advance
Lexaria&#146;s IP. </P>
<P align=justify>Initial<I> in vitro</I> human intestinal cell absorption
studies conducted by the Company in 2015 for non-psychoactive cannabinoids
reported increases in cannabinoid absorption at that time in the range of 325%
to 499%.</P>
<P align=justify>The complete R&amp;D program of 2017 and 2018 represents
roughly a 10-fold increase in the third-party laboratory work previously
contracted by Lexaria and is expected to provide the foundation for increased
licensing opportunities in market sectors as yet untouched by Lexaria. The
Company expects many new business opportunities to arise as a result of
successful R&amp;D results. </P>
<P align=justify>Included within this budget is intellectual property pursuit in
the USA, Canada and around the world. Lexaria currently has a total of 18
patents pending, and patent applications filed in more than 40 countries around
the world. Lexaria&#146;s existing financial resources are sufficient to aggressively
pursue positive outcomes within this large IP portfolio. </P>
<P align=justify>Additional information on planned R&amp;D programs will be
released soon. </P>
<P align=justify><B>About Lexaria </B></P>
<P align=justify>Lexaria Bioscience Corp. is a food biosciences company with a
proprietary technology for improved delivery of bioactive compounds. The
Company&#146;s lipophilic enhancement technology has been shown to enhance the
bioavailability of orally ingested cannabinoids, while also masking taste. This
technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company&#146;s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <U>www.lexariabioscience.com</U></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT: <BR>Lexaria Bioscience
Corp.<BR>Chris Bunka <BR>Chairman &amp; CEO <BR>(250) 765-6424 </P>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Factors which could cause actual results to differ materially from
those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance that Lexaria will successfully complete any other
contemplated or existing technology license agreements, nor that Lexaria&#146;s
technology will deliver any improvement in taste or bioavailability with any
reliability nor across any product category. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever, nor that any patent application in the USA or any
other nation or under any treaty will result in the award of an actual patent;
nor that an award of any actual patent will protect against challenges from
unknown third parties. There is no assurance that any of Lexaria&#146;s postulated
uses, benefits, or advantages for the patent-pending technology will in fact be
realized in any manner or in any part. No statement herein has been evaluated by
the Food and Drug Administration (FDA)or by Health Canada. Lexaria products are
not intended to diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
